News
German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million ...
BioNTech SE (BNTX) reports significant revenue growth and strategic advancements despite ongoing challenges in the COVID-19 ...
“In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by ...
BioNTech reaffirmed its fiscal year 2025 guidance of 1.7 billion-2.2 billion euros compared to the consensus of 2.05 billion ...
BioNTech (BNTX) stock gains as the company surpasses Q2 2025 forecasts with 103% YoY revenue growth, thanks mainly to Pfizer ...
4d
Asianet Newsable on MSNBioNTech Gets Price Target Bumps From BofA, Clear Street After Strong Q2, Oncology Pipeline Push
The German biotech firm reaffirmed its full-year guidance and reported lower operating expenses alongside a solid cash ...
BioNTech (BNTX) recently reported significant improvements in its financial performance, with quarterly sales nearly doubling compared to the previous year and a substantial reduction in net losses.
5d
InvestorsHub on MSNBioNTech shares climb over 2% as Q2 revenue doubles, Bristol Myers partnership boosts outlook
BioNTech SE (NASDAQ:BNTX) saw its shares rise 2.45% in pre-market trading Monday following a strong second-quarter report ...
Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results